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As the major burden of Buruli ulcer disease (BUD) occurs in remote rural areas, develop-
ment of point-of-care (POC) tests is considered a research priority to bring diagnostic ser-
vices closer to the patients. Loop-mediated isothermal amplification (LAMP), a simple,
robust and cost-effective technology, has been selected as a promising POC test candi-
date. Three BUD-specific LAMP assays are available to date, but various technical chal-
lenges still hamper decentralized application. To overcome the requirement of cold-chains
for transport and storage of reagents, the aim of this study was to establish a dry-reagent-
based LAMP assay (DRB-LAMP) employing lyophilized reagents.
Methodology/Principal Findings
Following the design of an IS2404 based conventional LAMP (cLAMP) assay suitable to
apply lyophilized reagents, a lyophylization protocol for the DRB-LAMP format was devel-
oped. Clinical performance of cLAMP was validated through testing of 140 clinical samples
from 91 suspected BUD cases by routine assays, i.e. IS2404 dry-reagent-based (DRB) PCR,
conventional IS2404 PCR (cPCR), IS2404 qPCR, compared to cLAMP.Whereas qPCR ren-
dered an additional 10% of confirmed cases and samples respectively, case confirmation
and positivity rates of DRB-PCR or cPCR (64.84% and 56.43%; 100% concordant results in
both assays) and cLAMP (62.64% and 52.86%) were comparable and there was no signifi-
cant difference between the sensitivity of the assays (DRB PCR and cPCR, 86.76%; cLAMP,
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83.82%). Likewise, sensitivity of cLAMP (95.83%) and DRB-LAMP (91.67%) were compara-
ble as determined on a set of 24 samples tested positive in all routine assays.
Conclusions/Significance
Both LAMP formats constitute equivalent alternatives to conventional PCR techniques. Pro-
vided the envisaged availability of field friendly DNA extraction formats, both assays are
suitable for decentralized laboratory confirmation of BUD, whereby DRB-LAMP scores with
the additional advantage of not requiring cold-chains. As validation of the assays was con-
ducted in a third-level laboratory environment, field based evaluation trials are necessary to
determine the clinical performance at peripheral health care level.
Author Summary
Buruli ulcer disease (BUD) mainly occurs in remote rural areas of Sub-Saharan Africa, affects
skin and soft tissue, and may lead to severe disabilities. Therefore, early diagnosis and treat-
ment with antimycobacterial therapy are essential whereby theWHO recommends labora-
tory confirmation of 70% of the cases. As the current diagnostic gold standard (polymerase
chain reaction [PCR]) is restricted to third-level laboratories, development of confirmatory
point-of-care (POC) tests for BUD applicable at primary health care level has become a
research priority to bring diagnosis closer to where the patients are. Loop-mediated isother-
mal amplification (LAMP) has been selected by theWHO as one of the promising candidate
technologies for POC tests. The aim of this study was to establish and validate a LAMP assay
applying lyophilized reagents which are stable at ambient temperature, thus avoiding the
need for cold-chains. The results from this study suggest that the assay provides a valuable
alternative to other PCR tests as currently used for laboratory confirmation of BUD.
Introduction
Buruli ulcer disease (BUD), caused byMycobacterium ulcerans, is an infectious disease affect-
ing skin, soft tissues and sometimes the bones. The major endemic foci occur in rural areas of
Sub-Saharan Africa where BUDmainly affects children below the age of 15 years.
Antimycobacterial therapy can cure up to 80% of patients diagnosed in early stages of the
disease. If treated in advanced stages or left untreated, extensive destruction of tissue followed
by fibrous scarring and contractures may lead to severe sequelae such as functional limitation of
affected joints, which occur in up to 25% of cases. In the absence of proven preventive strategies,
early diagnosis and treatment are therefore crucial to avoid disease related disabilities [1–2].
The WHO recommends laboratory confirmation of at least 70% of clinically suspected
BUD cases per country [3]. Application of the 100%M. ulcerans specific diagnostic reference
standard for clinical samples, i.e. amplification of the multicopy insertion sequence (IS) 2404
by dry-reagent-based (DRB) PCR, conventional gel-based PCR (cPCR), or quantitative real-
time PCR (qPCR) requires fully equipped molecular biology units with highly-skilled person-
nel and is thus mostly restricted to tertiary (reference) level laboratories or national research
centres [4–9]. However, as the major burden of BUD exists in (remote) rural areas of endemic
countries and up to one-third of BUD cases are diagnosed in advanced category III stages [10–
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12], molecular IS2404 detection formats applicable as point-of-care (POC) tests are urgently
needed to bring diagnosis closer to where the patients live [13].
Behind this background, an expert group convened by the Foundation for New Innovative
Diagnostics (FIND) and the WHO in November 2013 selected loop-mediated isothermal
amplification (LAMP) as promising nucleic acid based candidate POC technology applicable
for decentralized diagnosis at primary health care level [14].
The salient features of LAMP technology are attributable to the Bacillus stearothermophilus-
derived Bst polymerase, which is characterized by strand-displacement activity (without 5’-3’ exo-
nuclease activity), enzyme activity at constant temperature (~ 65 +/- 3°C) without the need of
steps for denaturation of double-stranded DNA or primer annealing at different temperatures,
high amplification efficiency (up to 1010 copies in 60 minutes) and low susceptibility to classical
PCR inhibitors (e.g. melanin, collagen, humic acids). Furthermore, the ability to specifically
amplify target sequences by the use of four distinct primers recognizing 6 distinct regions in a sin-
gle step without the need for sophisticated laboratory equipment made this nucleic acid detection
method promising as POC test. LAMP applications were thus established and validated for the
diagnosis of various human pathogens such as (protozoan) parasites (e.g. Plasmodium falciparum,
Leishmania spp., Trypanosoma brucei, Giardia duodenalis, Schistosomamansoni/haematobium,
Taenia solium), bacteria (e.g. Listeria monocytogenes, Staphylococcus aureus,Mycobacterium
tuberculosis) as well as viruses and fungi in settings with limited resources [15–25].
To date, three different LAMP assays for laboratory confirmation of BUD were published.
The assay described by de Souza et al. targets the enoyl reductase gene of theM. ulcerans viru-
lence plasmid, technical validation of the assay however was conducted only on a limited num-
ber of samples [26]. Njiru et al. and Ablordey et al. reported two LAMP assays amplifying
different regions of the IS2404 ofM. ulcerans. Both assays underwent validation on various
clinical and environmental samples of BUD patients and infected animals from Ghana and
Australia, were 100%M. ulcerans specific (without any false positive result) and revealed ana-
lytical sensitivities of 20 [27] as well as 30–300 [28] copies of the respective IS2404 target
sequence, which equals 0.1 to 1.5 genome equivalents ofM. ulcerans, respectively. These ana-
lytical sensitivities approach that of cPCR [6, 27–28], but not that of qPCR [7, 29]. However,
both assays were evaluated under optimal laboratory conditions applying high-standard DNA
extraction and purification procedures in third level laboratories or national research centers,
which may not be practicable at primary health care level. To simulate technical feasibility
under field conditions, crude (i.e. boiled) DNA extracts were used without further purification
for LAMP testing of clinical samples and led to a significant decrease in sensitivity [28]. More-
over, all LAMP assays described so far require unlimited cold-chains as well as shipment of
reagents on dry-ice, which is a major cost factor for endemic settings and not always feasible at
decentralised facilities. Therefore, technical advancement of LAMP technology and DNA
extraction into utterly field friendly formats is unanimously recommended [27–28].
Against this background, the aim of this study was to establish an IS2404 detection based
LAMP assay employing lyophilized reagents (dry-reagent-based [DRB] LAMP) which provides
significant benefit for application under tropical climate conditions, to validate the assay on
clinical samples including fine needle aspirates (FNA) which were largely omitted in previous
studies, and to provide a prototype assay for future large-scale field testing.
Materials and Methods
Ethical statement
The study was approved by the Ghanaian KNUST (CHRPE/91/10) and the national Togolese
(14/2010/CRBS) ethics committees. All samples analyzed in this study were collected for
LAMP for Laboratory Confirmation of BUD
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004219 November 13, 2015 3 / 14
diagnostic purposes. Written informed consent was obtained from all study participants and/
or their legal representative, if aged below 18 years.
Study participants, clinical samples and data collection
Clinically suspected BUD patients were recruited from two study sites in Ghana (Agogo Pres-
byterian Hospital, Asante Akim North District, n = 12; Tepa Government Hospital, Ahafo Ano
North District, n = 20) and one study site in Togo (“Centre Hospitalier Régional de Tsévié”,
region “Maritime”, n = 59) and 140 diagnostic samples (FNA, n = 66; swab samples, n = 32;
punch biopsy samples, n = 42) were collected according to standardized procedures. Briefly,
swabs were taken by circling the undermined edges of ulcerative lesions, and FNA or 3mm
punch biopsies were obtained from the center of non-ulcerative lesions. Samples were trans-
ported to the Kumasi Center for Collaborative Research in Tropical Medicine (KCCR, Kumasi,
Ghana) or the “Institut National d’Hygiène” (INH, Lomé, Togo) in 2 ml screw cap tubes con-
taining 700 μl (swab and punch biopsy samples) or 300 μl (FNA samples) cell lysis solution
(CLS; Qiagen, Hilden, Germany) within one day at ambient temperature [10, 30–33].
Clinical, epidemiological and routine laboratory data were collected by means of WHO BU
01.N forms [34] and standardized project specific laboratory data entry forms, and were
entered in a web-based database as previously described [10].
Laboratory confirmation by PCR
Whole genome DNA was extracted from clinical samples in CLS at KCCR or INH using the
Gentra Puregene DNA extraction kit (Qiagen) with minor modifications of the manufacturer’s
instructions as described in S1 Protocol [6]. DNA extracts were stored at 4–8°C (up to one
week) or -18°C (long-term storage).
For routine on-site laboratory confirmation DNA extracts were subjected to IS2404 DRB
PCR at KCCR and INH as previously described [6, 10, 35]. For comparative testing in the con-
text of external quality assurance programs with conventional, gel-based IS2404 PCR (cPCR)
[4–5, 33, 35, 36] and a recently described modified IS2404 qPCR based on the assay published
by Fyfe et al. [7, 29] aliquots of DNA extracts were shipped to the Department of Infectious
Diseases and Tropical Medicine (DITM), Munich, Germany by courier service at ambient tem-
perature [10].
Development of an IS2404 detection-based LAMP assay
The development and validation of the LAMP assay was conducted in the laboratories of
DITM.
DNA extracts. For establishment and technical validation of an IS2404 LAMP assay,
sequencing confirmed DNA extracts of fiveM. ulcerans strains from cultures (i.e. “must detect”
samples), twelve mycobacterial species (i.e. “must not detect” samples:M. avium,M. chelonae,
M. fortuitum,M. gordonae,M. intracellulare,M. kansasii,M.marinum,M. smegmatis,M. szul-
gai,M. tuberculosis,M. xenopi andM. lentiflavum) were available at DITM [29, 37–38].
IS2404 plasmid standard. To generate a plasmid standard applicable as positive control
and calibration template with known copy numbers for regions amplified by gel-based IS2404
(DRB) PCR, IS2404 qPCR as well as the novel IS2404 LAMP assays, respectively, the complete
IS2404 sequence was amplified by conventional PCR from a sequencing confirmedM. ulcerans
culture extract. The primers were IS2404-fwd (5`-3`: ATG GCT TTG TTG GCG ATC GC)
and IS2404-rev (5`-3`: TTA GCA GGC TTG TGA GCT GG). The reaction mixture contained
13.5 μl molecular grade H2O (Carl Roth, Karlsruhe, Germany), 2.5 μl 10-fold PCR buffer for
Thermococcus kodakaraenis (KOD) derived DNA polymerase (Merck, Darmstadt, Germany),
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2.0 μl MgSO4, 2.5 μl dNTP mix (2 mM each), 10 pmol of each primer, 2 μl DNA template and
0.5 μl KOD Hot-Start Polymerase (Merck). The amplification was performed at 95°C for 2
min., followed by 35 cycles of 95°C for 20 sec., 57°C for 15 sec., 70°C for 20 sec. and a final
incubation at 70°C for 2 min. The PCR product was purified from a 1.2% agarose TAE gel by
means of the Double Pure Kit (Bio&SELL, Feucht, Germany) according to the manufacturer’s
instructions. Then, a 3’A-overhang was added to the purified PCR product by incubating the
following reaction mixture for 20 minutes at 72°C: 38 μl purified PCR product, 5 μl PCR-reac-
tion buffer (10-fold), 5 μl MgCl2 (25 mM), 1 μl dATP (10 mM), 1 μl Taq polymerase (Bio&-
SELL, each). The ‘A’-tailed PCR product was again purified with the Double Pure Kit and then
ligated into a pGEM-T-vector (Promega, Mannheim, Germany) using the following reaction
mixture incubated at 4°C overnight: 5 μl 2-fold Rapid Ligation Buffer, 3 μl DNA (with 3’A-
overhangs), 1 μl pGEM-T-vector and 1 μl T4 DNA Ligase. For cloning the plasmid to bacteria,
2 μl of the ligation reaction were mixed with 50 μl E. coli JM109 z-competent cells (Zymo, Frei-
burg, Germany), inoculated onto LB agar plates with 100 mg/L ampicillin (Carl Roth) and
incubated at 37°C overnight. The selected E. coli clone was cultivated in 5 ml LB medium with
100 mg/L ampicillin (Carl Roth), incubated at 37°C overnight and then subjected to plasmid
preparation using the matrix-based HiYield Plasmid Mini kit (Süd-Laborbedarf, Gauting, Ger-
many) according to the manufacturer’s specification. The cloned plasmid sequence was con-
firmed by direct DNA sequencing as previously described [37]. Purity of extracted IS2404
plasmids was assessed by photometry on a BioPhotometer plus (Eppendorf, Wesseling-Berz-
dorf, Germany) and agarose gel-electrophoresis on a 1% TAE gel. Quantification of plasmid
DNA extracts was done using the fluorescence quantification kit “Quant-It dsDNA Broad
Range” on a Qubit (Life Technologies, Karlsruhe, Germany) according to the manufacturer’s
instruction and plasmid standards were adjusted to 106 copies per μl.
Analytical sensitivity was determined as lower limit of detection (LOD), i.e. lowest template
concentration rendering positive amplification of 95% of samples. The LOD of each assay
(including DRB PCR, cPCR and qPCR) was determined at DITM using the plasmid standard
in 10-fold serial dilutions [39].
IS2404 LAMP primers. A set of four primers was designed for amplification of theM.
ulcerans specific IS2404 by manually analyzing the target sequence and designing the primers
according to the needs for LAMP amplification. Specificity of the primers forM. ulcerans was
confirmed in silico by means of the basic local alignment search tool (BLAST, GenBank,
NCBI) [40]. The primer set consisted of two smaller oligonucleotides with forward (MU2-F3)
and reverse complementary (MU2-B3) sequences and two larger oligonucleotides (MU2-FIP
and MU2-BIP) with a complex sequence construction. Primer sequences are provided in
Table 1 and binding sites within the IS2404 are displayed in Fig 1. Primers MU2-B3 and
MU2-BIP were first published by Ablordey et al. [28].
Conventional IS2404 LAMP (cLAMP) protocol. Each cLAMP reaction mix consisted of
1 μl Bst DNA polymerase (large fragment, 8 U/μl; New England Biolabs [NEB], Frankfurt am
Main, Germany), 1.0 μl dNTP mix (2 mM each, Merck), 1.0 μl of primers MU2-F3 and
MU2-B3 (5 pmol/μl) and 2.0 μl of primers MU2-FIP and MU2-BIP (10 pmol/μl), respectively
(TibMolBiol, Berlin, Germany), 2.0 μl betaine (5 M; Sigma-Aldrich, Taufkirchen, Germany),
2.5 μl 10-fold Thermopol buffer for Bst DNA polymerase (NEB) and 11.5 μl molecular grade
H2O (Carl Roth). Following the addition of 1 μl DNA extract (template), cLAMP reactions
(final volume: 25 μl) were carried out in 1.5 ml SafeSeal reaction tubes (Sarstedt, Nümbrecht,
Germany) at 65°C for 60 minutes in a conventional thermoblock (HLC Thermomixer MKR
13, HLC BioTech, Bovenden, Germany) and a final step at 80°C for 10 minutes terminated the
amplification.
Each run included negative extraction and no template (H2O) as well as positive controls.
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Table 1. Primer sequences of the IS2404 LAMP assay.
Primer Sequence (forward) Sequence (reverse
complementary)
Complete sequencea
MU2-F3 ACT GCG GAA TCG AGA ACA
G
N/A ACT GCG GAA TCG AGA ACA G
MU2-B3b N/A CGG TTG GCG GTC AAA GC CGG TTG GCG GTC AAA GC
MU2-FIP GTG CGC CGT GTC TGG TAT
GTG G
GTG CGC CGT GTC TGG TAT GTG GCT GCA CTG GAT ACG
CGA CG
CTG CAC TGG ATA CGC GAC
G
MU2-BIPc AGG TCC TAG CAA CGC TAC
GCA
AGG TCC TAG CAA CGC TAC GCA AAT CCG GCA GGC TTC
GG
AAT CCG GCA GGC TTC GG
Table 1 shows the sequences of a set of four M. ulcerans specific LAMP primers targeting the IS2404.
N/A, not applicable.
a The reverse complementary sequence of nucleotides is displayed in italics.
b MU2-B3, the same primer sequence was originally published by Ablordey et al. as primer “Buruli-B3” [28].
c MU2-BIP, the same primer sequence was originally published by Ablordey et al. as primer “Buruli-BIP” [28].
doi:10.1371/journal.pntd.0004219.t001
Fig 1. Binding sites of LAMP primers within the IS2404. Fig 1 shows binding sites of LAMP primers within the IS2404 ofM. ulcerans strain Agy 99
(Genbank accession number: CP000325.1). Primer MU2-FIP consists of a first reverse complementary region “F1” and a second forward region “F2”. Primer
MU2-BIP (first described by Ablordey et al. [28]) consists of a first forward region “B1” and a second reverse complementary region “B2”. Primers and
corresponding regions are highlighted in colors; red: primer MU2-F3 (region “F3”); yellow: primer MU2-FIP (region “F2”); light blue: primer MU2-FIP (region
“F1”); dark blue: primer MU2-BIP (region “B1”); green: primer MU2-BIP (region “B2”) and pink: primer MU2-B3 (region “B3”; first described by Ablordey et al.
[28]).
doi:10.1371/journal.pntd.0004219.g001
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IS2404 dry-reagent-based LAMP (DRB LAMP) protocol. The DRB LAMP reaction mix
contained the same concentrations of reagents and primers as described for the conventional
LAMP assay. However, as the wildtype Bst polymerase large fragment contained glycerol it was
not possible to lyophilize. Therefore, a customized Bst polymerase dissolved in H2O and reac-
tion buffer (NEB) were applied for the DRB LAMP assay. The DRB LAMP reaction mix was
prepared for each reaction in 1.5 ml reaction tubes and subjected to lyophilization by means of
a RVC 2–25 CD plus Vacuum Concentrator (Christ, Osterode, Germany) at 1.0 mbar and a
safety pressure of 1.000 mbar according to the manufacturer’s specifications. During the pro-
cess of validation, DRB LAMP reaction tubes were stored at ambient temperature in the dark
and reactions were carried out within one week after lyophilization as described for cLAMP
following the addition of 1 μl template DNA and adjustment with 24 μl molecular grade H2O
(Carl Roth) to a final reaction volume of 25 μl.
LAMP product visualization. LAMP products were detected by two different methods: i)
gel-electrophoresis on a 0.5x TBE gel containing 0.01% GelRed (Biotium, Cologne, Germany)
and ii) SYBR Green I (Life Technologies) staining (0.5 μl of 1:5 diluted SYBR Green I staining
solution and 12.5 μl of LAMP product) followed by UV-transillumination.
Comparative testing of clinical samples
Confirmation rates of routine assays (PCR [DRB PCR, cPCR] and qPCR) compared
with cLAMP. The confirmation rate was defined as the number of patients with a positive
PCR, qPCR or cLAMP test result divided by the number of all suspected BUD cases.
Sensitivity rates of PCR (DRB PCR, cPCR) and cLAMP among confirmed BUD
patients. The sensitivity rate was defined as the number of patients with a positive PCR or
cLAMP test result divided by the number of all qPCR confirmed patients.
Positivity rates of routine assays (PCR [DRB PCR, cPCR] and qPCR) and cLAMP
among clinical samples from suspected BUD cases. The positivity rate was defined as the
number of clinical samples from suspected BUD cases with a positive PCR, qPCR or cLAMP
test result divided by the number of all samples tested.
Sensitivity rates of routine assays (PCR [DRB PCR, cPCR]) compared with cLAMP
among clinical samples from confirmed BUD cases. The sensitivity rate was defined as the
number of clinical samples from confirmed BUD patients with a positive PCR or cLAMP test
result divided by the number of all samples with a positive qPCR result.
Positivity rates of DRB LAMP compared with routine assays (PCR [DRB PCR, cPCR]
and qPCR) and cLAMP among clinical samples from suspected BUD cases. The positivity
rate was defined as the number of clinical samples with a positive PCR, qPCR or cLAMP test
result divided by the number of all samples tested.
Sensitivity rates of cLAMP and DRB LAMP among clinical samples from confirmed
BUD cases. The sensitivity rate was defined as the number of clinical samples from confirmed
BUD patients with a positive cLAMP or DRB LAMP test result divided by the number of all
samples with a positive result in DRB PCR, cPCR and qPCR each.
Statistical analysis
The study was observational and transversal (cross-sectional study design). An approximative
test (McNemar chi-square test for matched pairs of samples with categorical test results) and
estimation of standard error of proportion (to calculate 95 percent confidence intervals [95%-
CI] of categorical test results) were conducted. Significant differences were defined as P-values
below 0.05 or as not overlapping of 95%-CI of proportions.
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Results
Performance characteristics of routine assays (DRB PCR, cPCR and
qPCR) compared with cLAMP
In silico analysis of the novel IS2404 LAMP primers and testing of 17 DNA extracts from
mycobacterial cultures (M. ulcerans, n = 5; other mycobacteria, n = 12) by cLAMP and DRB
LAMP revealed 100% specificity of both assays forM. ulcerans. The LODs were 50 (DRB PCR
and cPCR), 3 (qPCR) and 100 (cLAMP) copies of the target sequence IS2404, corresponding to
0.2, 0.01, and 0.5M. ulcerans genome equivalents, respectively.
Laboratory confirmation of suspected BUD cases
Out of the 91 patients with suspected BUD, 68 were laboratory confirmed as BUD patients
(74.73%) by routine methods. Among 68 confirmed BUD patients, 40 patients (58.82%) were
in age group 5–14 years (age range 5–56 years, mean 14 years, median 11 years), 33 patients
(48.53%) were male, and 36 patients (52.94%) presented with non-ulcerative lesions.
Confirmation rates of routine assays (DRB PCR, cPCR and qPCR)
compared with cLAMP among suspected BUD cases
DRB PCR (on-site at KCCR or INH) and cPCR (DITM, 100% concordance between DRB and
cPCR results) confirmed 59/91 (64.84%; 95%-CI: 55.02%-74.65%) of the suspected BUD cases,
the qPCR confirmed 68/91 (74.73%; 95%-CI: 65.80%-83.65%), thus added an additional diag-
nostic yield of 9.89%. The confirmation rate for cLAMP was 62.64% (95%-CI: 52.70%-72.58%;
n = 57). Neither DRB PCR nor cPCR or cLAMP had false positive results compared with
qPCR, and confirmation rates were not significantly different. According to McNemar test,
there was no significant difference between DRB PCR or cPCR (100% concordant results)
compared with qPCR (ORcrude = 1.60; 95%-CI: 0.81–3.20; P-value = 0.15), between cLAMP
compared with qPCR (ORcrude = 1.76; 95%-CI: 0.89–3.50; P-value = 0.08) and between DRB
PCR or cPCR compared with cLAMP (ORcrude = 1.10; 95%-CI: 0.57–2.11; P-value = 0.76).
Sensitivity rates of DRB PCR, cPCR and cLAMP among confirmed BUD
cases
Among the 68 BUD cases confirmed by qPCR, the sensitivity was 86.76% (95%-CI: 78.71%-
94.82%; n = 59) for DRB PCR and cPCR and 83.82% (95%-CI: 75.07%-92.58%; n = 57) for
cLAMP. According to McNemar test, there was no significant difference between DRB PCR
and cPCR compared with cLAMP (ORcrude = 1.27; 95%-CI: 0.44–3.63; P-value = 0.63).
Positivity rates of routine assays (DRB PCR, cPCR and qPCR) and
cLAMP among clinical samples from suspected BUD cases
Among the 140 samples from 91 clinically suspected BUD cases, the positivity rate was 56.43%
(95%-CI: 48.21%-64.64%; n = 79) for DRB PCR and cPCR, 67.14% (95%-CI: 59.36%-74.92%;
n = 94) for qPCR, and 52.86% (95%-CI: 44.59%-61.13%; n = 74) for cLAMP. Neither DRB
PCR nor cPCR or cLAMP revealed false positive results compared with qPCR. According to
McNemar test, there was no significant difference between DRB PCR or cPCR compared with
qPCR (ORcrude = 1.58; 95%-CI: 0.94–2.64; P-value = 0.07) and between DRB PCR or cPCR
compared with cLAMP (ORcrude = 1.16; 95%-CI: 0.70–1.90; P-value = 0.55), whereas the differ-
ence between cLAMP compared with qPCR was significant (ORcrude = 1.82; 95%-CI: 1.09–
3.05; P-value = 0.02).
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Stratification into sample types did not reveal significant differences in positivity rates of
DRB PCR, cPCR, qPCR and cLAMP among FNA, swab or punch biopsy samples.
Sensitivity rates of routine assays (DRB PCR and cPCR) compared with
cLAMP among clinical samples from confirmed BUD cases
Among the 94 samples from 68 BUD cases confirmed by qPCR, the sensitivity was 84.04%
(95%-CI: 76.64%-91.45%; n = 79) for DRB PCR and cPCR, and 78.72% (95%-CI: 44.59%-
61.13%; n = 74) for cLAMP. According to McNemar test, there was no significant difference
between DRB PCR or cPCR compared with cLAMP (ORcrude = 1.42; 95%-CI: 0.64–3.18); P-
value = 0.35).
Performance characteristics of DRB LAMP
DRB LAMP revealed the same performance characteristics as determined for cLAMP (i.e.
100%M. ulcerans specificity and a LOD of 0.5M. ulcerans genome equivalents).
Positivity rates of DRB LAMP compared with routine assays (DRB PCR,
cPCR and qPCR) and cLAMP among clinical samples from suspected
BUD cases
To compare DRB LAMP with DRB PCR, cPCR, qPCR and cLAMP, 32 samples (FNA and
swab samples, n = 16, respectively) from 32 suspected BUD cases were subjected to the assays.
The positivity rate was 75.0% (95%-CI: 62.41%-87.59%; n = 24) for DRB PCR, cPCR and
qPCR, 71.88% (95%-CI: 87.84%-100%; n = 23) for cLAMP, and 68.75% (95%-CI: 80.61%-
100%; n = 22) for DRB LAMP. Neither cLAMP nor DRB LAMP revealed false positive results
compared with DRB PCR, cPCR and qPCR.
According to McNemar test, there was no significant difference neither between DRB PCR,
cPCR or qPCR compared with cLAMP (ORcrude = 1.17; 95%-CI: 0.34–4.10; P-value = 0.78),
nor between DRB PCR, cPCR or qPCR compared with DRB LAMP (ORcrude = 1.36; 95%-CI:
0.40–4.49; P-value = 0.58), nor between cLAMP compared with DRB LAMP (ORcrude = 0.86;
95%-CI: 0.26–2.87; P-value = 0.79).
Sensitivity rates of cLAMP and DRB LAMP among clinical samples from
confirmed BUD cases
Among the 24 samples from 24 BUD patients confirmed by DRB PCR, cPCR and qPCR, the
sensitivity was 95.83% (95%-CI: 87.84%-100%; n = 23) for cLAMP and 91.67% (95%-CI:
80.61%-100%; n = 22) for DRB LAMP. According to McNemar test, there was no significant
difference between cLAMP compared with DRB LAMP (ORcrude = 0.48; 95%-CI: 0.02–7.54);
P-value = 0.56).
IS2404 LAMP detection methods
Out of 74 amplicons derived from cLAMP reactions, 74/74 (100%) were judged positive by gel-
electrophoresis and 73/74 (98.65%) by SYBR Green I staining. All products derived from DRB
LAMP were likewise analyzed and the concordance rate was 22/22 (100%) between both detec-
tion methods.
Table 2 shows confirmation rates, sensitivity, specificity and significance of the applied
molecular tests.
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Discussion
BUD belongs to the currently five neglected diseases in line for the IDM (innovative and inten-
sified disease management) approach demanding a major scaling up of active detection, treat-
ment, monitoring and surveillance. Development of diagnostic tests that bring health services
closer to where NTDs are is considered a research priority. LAMP, a technology that features
cost effectiveness, robustness and modest needs in terms of equipment, has recently been
selected by the WHO as one of the promising tools for decentralized diagnostics [13–14, 41].
Several investigators recently succeeded in developingM. ulcerans specific LAMP assays
which showed performance characteristics comparable to conventional PCR formats [26–28].
Based on longstanding experience with a DRB PCR format for laboratory confirmation of
BUD in Ghana and Togo [6, 10, 30, 33, 36, 42], the development of a DRB LAMP assay
Table 2. Confirmation rates, sensitivity, specificity and significance of the appliedmolecular tests.
Number of BUD cases Number of samplesa Statistical parameter DRB PCR and cPCRb qPCR cLAMP DRB LAMP
91 suspected 140 Positive results 59 68 57 N.A.
Confirmation rate [%] 64.84 74.73 62.64 N.A.
95%-CIc [%] 55.02–74.65 65.80–83.65 52.70–72.58 N.A.
Specificityd [%] 100 N.A. 100 N.A.
68 confirmede 140 Positive results 59 68 57 N.A.
Sensitivity [%] 86.76 N.A. 83.82 N.A.
95%-CIc [%] 78.71–94.82 N.A. 75.07–92.58 N.A.
91 suspected 140# Positive results 79 94 74 N.A.
Positivity rate [%] 56.43 67.14* 52.86* N.A.
95%-CIc [%] 48.21–64.64 59.36–74.92 44.59–61.13 N.A.
Specificityd [%] 100 N.A. 100 N.A.
68 confirmede 94# Positive results 79 94 74 N.A.
Sensitivity [%] 84.04 100 78.72 N.A.
95%-CIc [%] 76.64–91.45 N.A. 44.59–61.13 N.A.
32 suspected 32 Positive results 24 24 23 22
Positivity rate [%] 75.00 75.00 71.88 68.75
95%-CIc [%] 62.41–87.59 62.41–87.59 87.84–100 80.61–100
Specificityd [%] 100 N.A. 100 100
24 confirmede 24 Positive results N.A. N.A. 23 22
Sensitivity [%] N.A. N.A. 95.83 91.67
95%-CIc [%] N.A. N.A. 87.84–100 80.61–100
Specificityd [%] N.A. N.A. 100 100
Table 2 shows the results of DRB PCR, cPCR, qPCR, cLAMP, and DRB LAMP from clinical samples of clinically suspected and confirmed BUD cases
recruited at Agogo Presbyterian Hospital, Ghana, Tepa Government Hospital, Ghana, and at Centre Hospitalier Régional de Tsévié, Togo.
N.A., not applicable.
a Number of clinical samples tested.
# indicates if the presented results refer to the number of samples–all other results refer to the number of patients or ¶the number of patients and samples
was equal.
b Results of the DRB PCR and cPCR were 100% concordant for all samples tested.
c 95 percent confidence interval.
d Specificity was calculated as proportion of truly positive test results out of all positive results of the same test, based on the results of qPCR as reference
test.
e Laboratory confirmation was defined as positive IS2404 qPCR test result of any sample tested per patient.
* Significantly different proportions of positive results among all clinical samples tested by two different tests, calculated by McNemar test.
doi:10.1371/journal.pntd.0004219.t002
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applicable under tropical climate conditions at primary health care level was envisaged in this
study. Thermodynamic reasons (i.e. leaving out an initial denaturation step for annealing of
primers) required the design of modified primers, therefore as a first step a new cLAMP assay
was established that constituted the basis for the DRB format. During development of the DRB
assay lyophilization of the reaction mix initially constituted a major challenge. Due to the glyc-
erol content of Bst polymerase and reaction buffer as employed in previous cLAMP formats
(including our own), customized glycerol-free reagents had to be obtained and adequate lyoph-
ilization protocols had to be established.
The comparable performance of cLAMP, DRB LAMP and DRB PCR as well as cPCR sug-
gests that both LAMP formats constitute a reliable alternative to conventional routine assays.
Our data also show that the LAMP assays and the DRB PCR as well as cPCR have equal sensi-
tivity for FNA samples. Both LAMP formats are applicable at primary health care level, the
DRB format however provides significant advantages such as a simplified test layout and the
possibility of storage of reagents at ambient temperature. Decentralized utilization of LAMP
technology furthermore would lead to cost saving due to reduced expenditures for transporta-
tion of samples to a reference center as well as reduced test costs, i.e. US$ 1–2 per LAMP reac-
tion as compared to US$ 8–10 per DRB PCR or cPCR reaction.
In this study it was not possible to assess long-term storage of DRB-LAMP reaction tubes
under tropical conditions. Long-term storability of DRB PCR reaction tubes was however pre-
viously proven [6, 36] which allows the conclusion that maximum storage periods of up to 12
months also apply for LAMP reagents.
Although in our study routine PCR and LAMP assays for the most part did not perform sig-
nificantly different from qPCR, it must be assumed that qPCR renders an additional diagnostic
yield of approximately 10% [10]. Therefore, regardless of the method used, confirmation of
negative samples by qPCR e.g. through the global network of laboratories for confirmingM.
ulcerans infection [43] should be attempted. Likewise, participation of laboratories in external
quality assurance programs as implemented by Eddyani et al. in collaboration with the WHO
is strongly recommended [44].
While the amplification procedure of LAMP technology especially in the DRB format can
be considered field friendly without restriction, current DNA extraction procedures are not yet
entirely appropriate for POC testing and need optimization. As shown by Ablordey et al. the
use of boiled crude DNA extracts led to a significant decrease in sensitivity [28]. Other options
such as one-tube silica-membrane based extraction protocols [45] or one-tube enzyme-based
lyophilized reactions are yet to be evaluated. A field friendly approach to storage of DNA
extracts for purposes of quality assurance could be the filter paper technology as successfully
applied for TBC [46].
In conclusion, the cLAMP and DRB LAMP formats evaluated in this study are equivalent
alternatives to conventional PCR techniques and, provided the availability of field friendly
DNA extraction formats, constitute valuable tools for decentralized laboratory confirmation of
BUD. As in the case of other investigators who previously developed BUD specific LAMP
assays, the validation of the LAMP assays presented in this study was conducted in a third-
level laboratory environment, therefore field based evaluation trials are necessary to determine
the clinical performance at peripheral health care level.
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